Evidence of Liver Transplantation
Conditions
Keywords
Melatonin, liver transplant, oxidative stress
Brief summary
Impact of melatonin on organ donor pretreatment and liver transplant recipient: prospective, randomized, double-blind trial. OBJECTIVES. To establish the efficacy of the melatonin administered to encephalic death donors (EDD) in liver transplantation. The aim is to improve the functional quality of the retrieved organs, attenuate lesions and ischemia-reperfusion mediators, and provide grafts with greater resistance to post-transplant aggression. METHODOLOGY. Prospective, randomized, double-blind, pilot trial to evaluate preconditioning with melatonin versus placebo in EDDs. Two groups, melatonin and control-placebo, n=30 per group. Administration to donor via NG tube of 30mg of melatonin or placebo (lactose) upon inclusion in the trial, 60 minutes prior to commencement of surgery and following laparotomy during extraction. Evaluation of response to treatment: A) Conventional clinical, hemodynamic, analytical and histopathological parameters in donor and recipient. B) Plasma determinations for: oxidative/nitrosative stress; acute phase proteins; cellular and humoral immunity; NT-proBNP and cystatin C; endocrine profile; melatonin levels. C) Determinations in liver tissue: quantification of malonyldialdehyde-4hydroxyalkenals and protein carbonyl content; cellular and mitochondrial membrane fluidity; markers of tissue-vascular damage and proliferation: transforming growth factor-beta (TGF-β); hypoxia-inducible factor (HIF) and vascular endothelial growth factor (VEGF). Data will be analyzed following a prospectively define plan and by intention-to-treat analysis.
Detailed description
This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by the Health Science Aragon Institute and its principal investigator is F. Agustín García Gil (Surgical Service). It will start in April-May 2013 and will finish 12 months later approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences).
Interventions
DRUGMelatonin
Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
DRUGPlacebo
Sponsors
Fondo de Investigacion Sanitaria
Aragon Institute of Health Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 68 Years
Healthy volunteers
No
Inclusion criteria
A) Donors 1. Encephalic-death (ED) organ donor who is situated in the ICUs of accredited hospitals in Zaragoza and meets each and every one of the following criteria. 2. Being 16 years old or older. 3. Informed consent for the donation signed by the immediate family. 4. Informed consent for inclusion of the donor in the study . 5. Receive intensive treatment and standard maintenance of the donor in ED, in accordance with universally accepted protocols of the Organizacion Nacional de Trasplantes (ONT), of the Aragon Autonomous Transplant Coordination, and of the ICUs and the participating hospitals in the study. B) Liver transplant recipients 1. Being 18 years old or older and being less than 68 years of age. 2. Informed consent for the procedure of LT signed. 3. Informed consent for patient inclusion in the study, signed the same day that consent to the LT.
Exclusion criteria
A) Donors A potential encephalic-death organ donor will not be included in the study if either of the following criteria: 1. Absence of either signed informed consent: for organ donation or for inclusion in the study. 2. No standard concomitant treatment and management of donor in ED. B) Liver transplant recipients 1. Absence of either signed informed consent: for liver transplantation or for inclusion in the study. 2. Split, domino or multiorgan transplantation. 3. Grafts removed by other surgical teams. 4. Pregnant women or fertile not using contraceptive measures highly effective.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AST levels | Between days 1 and 10 postoperatively. | Aspartate transaminase (AST) levels will be measured. |
| ALT | Between days 1 and 10 postoperatively | Alanine transaminase (ALT) levels will be measured. |
| Bilirubin levels | Between days 1 and 10 postoperatively | Bilirubin levels will be measured. |
| Prothrombin levels | Between days 1 and 10 postoperatively | Prothrombin levels will be measured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Donor and recipient serological parameters | Between days 1 and 10 postoperatively | Donor and recipient serological parameters |
| Post-reperfusion syndrome | Transplant day | Post-reperfusion syndrome |
| Morphological and functional quality of the liver graft evaluated by histological parameters of ischemia-reperfusion and tissue biochemical markers | Day 0 and day 1 | Morphological and functional quality of the liver graft evaluated by histological parameters of ischemia-reperfusion and tissue biochemical markers |
| No primary function and primary graft dysfunction | Transplant day | No primary function and primary graft dysfunction |
| Survival of the graft | From day 0 to 3 months | Survival of the graft |
| Patient survival | Day 0 to 3 months | Patient survival |
Countries
Spain
Outcome results
None listed